Knight Therapeutics Inc. (TSX: GUD), the Montréal-based pan-American pharmaceutical company, has been named to the Globe and Mail's Report on Business 2026 Canada's Top Growing Companies ranking, placing 345th out of 375 companies recognised this year. The company reported three-year revenue growth of 53%, earning its place in the annual editorial list for the sixth consecutive year. Investors may be watching this recognition as a signal of sustained commercial momentum across Knight's Canadian and Latin American operations.

Key Points

  • Knight Therapeutics Inc. (TSX: GUD) is a pan-American pharmaceutical company headquartered in Montréal, Canada.
  • The company ranked 345th on the Globe and Mail Report on Business 2026 Canada's Top Growing Companies list.
  • Knight recorded three-year revenue growth of 53%, qualifying it among 375 companies recognised in the 2026 ranking.
  • Investors may be watching the company's stated pipeline of more than 50 product launches completed or planned across Canada and Latin America.

Knight Therapeutics Earns Sixth Consecutive Spot on Report on Business Growth Ranking

Knight Therapeutics announced on September 25, 2026, that it has been included in the Globe and Mail's Report on Business Canada's Top Growing Companies list for the sixth consecutive year. The 2026 ranking placed Knight at position 345 among 375 qualifying companies. To be eligible for the voluntary programme, companies must complete a detailed application process and meet defined revenue requirements. The ranking is based on three-year revenue growth, and the full 2026 list along with editorial coverage appears in the October issue of Report on Business magazine.

53% Three-Year Revenue Growth Drives Knight's 2026 Recognition

The release states that Knight's inclusion was supported by three-year revenue growth of 53%. The company's operations span Canada and Latin America, where subsidiaries operate under the names United Medical, Biotoscana Farma, and Laboratorio LKM. According to the announcement, Knight has completed or has planned more than 50 product launches across these markets. The disclosure suggests this commercial activity across two major geographies has been a key contributor to the revenue trajectory that qualified the company for the ranking.

Samira Sakhia Highlights Team Execution Across Canadian and Latin American Markets

Samira Sakhia, President and Chief Executive Officer of Knight, is quoted in the release expressing that the recognition reflects the focus and execution of the company's teams in Canada and Latin America. She noted the company's commitment to delivering innovative products to physicians and improving patient health. Sakhia also referenced the more than 50 product launches as a factor in Knight's positioning for continued growth. No specific financial guidance or targets beyond the historical three-year growth figure were provided in the announcement.